Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?

Abstract Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide. Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma (PDAC) and numerous potential mechanisms have been demonstrated but much remains to be understood. To overcome the existing limitations in PC treatment, newer approaches targeting intrinsic or acquired mechanisms have been found to improve drug therapeutic effectiveness in PC patients. Here, we provide an update of the most recent findings and their implications for clinicians, and attempt to summarize the various aspects of different individualized novel therapies for PC that could most benefit metastatic PDAC patients..

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:8

Enthalten in:

Cancer Medicine - 8(2019), 14, Seite 6403-6413

Sprache:

Englisch

Beteiligte Personen:

Wenhao Luo [VerfasserIn]
Gang Yang [VerfasserIn]
Jiangdong Qiu [VerfasserIn]
Jingyang Luan [VerfasserIn]
Ying Zhang [VerfasserIn]
Lei You [VerfasserIn]
Mengyu Feng [VerfasserIn]
Fangyu Zhao [VerfasserIn]
Yueze Liu [VerfasserIn]
Zhe Cao [VerfasserIn]
Lianfang Zheng [VerfasserIn]
Taiping Zhang [VerfasserIn]
Yupei Zhao [VerfasserIn]

Links:

doi.org [kostenfrei]
doaj.org [kostenfrei]
doi.org [kostenfrei]
Journal toc [kostenfrei]

Themen:

Chemistry
Drug therapy
Metabolism
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Pancreatic cancer
Prevention

doi:

10.1002/cam4.2384

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

DOAJ040387895